Americas Gold and Silver Corporation
Change company Symbol lookup
Select an option...
USAS Americas Gold and Silver Corporation
YELP Yelp Inc
CCLV Karbon-X Corp
NCBDF Bandai Namco Holdings Inc
GTN Gray Television Inc
BKD Brookdale Senior Living Inc
PMT PennyMac Mortgage Investment Trust
EVTVD Envirotech Vehicles Inc
AUTL Autolus Therapeutics PLC
CLRMW Clarim Acquisition Equity Warrant Exp 05 Jan 2026 *W EXP 01/05/2026
Go

Materials : Metals & Mining | Small Cap Value
Based in Canada
Company profile

Americas Gold and Silver Corporation is a precious metals mining company in North America. The Company is engaged in acquisition, exploration, development and exploration of mineral resource properties in Mexico and the United States. The company is focused on three operating mines, including the San Rafael mine at its Cosala Operations in Mexico, the Galena Complex in Idaho, the United States and the Relief Canyon Mine in Nevada, the United States. The Cosala Operations are located in the state of Sinaloa, Mexico and consist of approximately 67 mining concessions that cover approximately 19,385 hectares. The Galena Complex is located in Idaho’s prolific Silver Valley, a district that is focused on producing silver, lead, zinc and copper from operations, such as the Bunker Hill, Sunshine and Lucky Friday mines. The Relief Canyon Mine is located in Pershing County, Nevada and the project encompasses an open pit mine and heap leach processing facility.

Price
Delayed
$0.683
Day's Change
-0.0097 (-1.40%)
Bid
--
Ask
--
B/A Size
--
Day's High
0.7073
Day's Low
0.6754
Volume
(Light)

Today's volume of 59,110 shares is on pace to be much lighter than USAS's 10-day average volume of 470,508 shares.

59,110

Talis Biomedical Announces First Quarter 2022 Financial Results

4:05 pm ET May 10, 2022 (Globe Newswire) Print

EQNX::TICKER_START (NasdaqGM:TLIS), EQNX::TICKER_END Talis Biomedical Corporation (Nasdaq: TLIS), a company dedicated to advancing health equity and outcomes through the delivery of accurate infectious disease testing in the moment of need, at the point of care, today reported financial results for the first quarter ended March 31, 2022.

Business update

-- Completed assessment of manufacturing processes and product design for manufacturing at scale and initiated necessary refinements.

-- Completed first release of Sia Dx(TM) cloud-based software on Talis One(TM) System.

-- Completed spending reduction plan to preserve cash.

"Following our assessment with independent experts, we remain confident there is a path to manufacturing at scale after addressing process modifications identified through this evaluation. Importantly, we do not believe there is an immediate need for substantial design or supply changes that would require extended timelines to validate," said Rob Kelley, chief executive officer of Talis Biomedical. "I am encouraged by the progress our team has made over the last 60 days toward validation of manufacturing scale-up for our Talis One COVID-19 Test System. With our continued focus on execution and cash preservation, we believe we are on the right path to deliver on our 2022 business objectives."

First Quarter 2022 Financial Results

Revenue was $3.2 million for the first quarter of 2022, compared to $7.0 million for the same period in 2021. This includes $2.3 million of product revenue for the first quarter of 2022 driven by antigen testing sales and $0.9 million of grant revenue.

Operating expenses were $32.6 million in the first quarter of 2022, compared to $67.5 million for the same period in 2021. The decrease in operating expenses was primarily driven by declines in research and development expenses as we near completion of investment in manufacturing scale-up.

Net loss was $33.1 million for the first quarter of 2022, compared to $60.5 million for the same period in 2021.

Unrestricted cash and cash equivalents on March 31, 2022, were $187.6 million.

Conference Call and Webcast Details

The company will host a live conference call and webcast to discuss these results and provide a corporate update on Tuesday, May 10, 2022, at 4:30 PM ET / 1:30 PM PT.

To participate in the call, please dial (833) 715-1329 (domestic) or (430) 775-1933 (international) and provide conference ID 8872347. The live webcast will be available on the News & Events page of the investors section of Talis Biomedical's website at talisbio.com.

About Talis Biomedical

Talis is dedicated to advancing health equity and outcomes through the delivery of accurate infectious disease testing in the moment of need, at the point of care. The company plans to develop and commercialize innovative products on its sample-to-answer Talis One(TM) system to enable accurate, low cost, and rapid molecular testing. The U.S. Food and Drug Administration (FDA) has granted Emergency Use Authorization (EUA) for use of the Talis One COVID-19 Test System in a variety of healthcare settings. For more information, visit talisbio.com.

Forward-Looking Statements

This press release may contain forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Words such as "may," "might," "will," "should," "believe," "expect," "anticipate," "estimate," "continue," "predict," "forecast," "project," "plan," "intend" or similar expressions, or other words that convey uncertainty of future events or outcomes can be used to identify these forward-looking statements. Forward-looking statements include statements regarding our intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things: our assessment of our manufacturing processes and product design; the ability of Sia Dx(TM) to be a comprehensive solution to consolidate patient test information and enhance organizational efficiency; our ability to validate manufacturing scale-up; and our ability to deliver on our business objectives, including cash preservation. These statements are not guarantees of future performance and are subject to certain risks, uncertainties and other factors that could cause actual results and events to differ materially and adversely from those indicated by such forward-looking statements including, among others: the impact to our business of the ongoing COVID-19 pandemic, including any impact on our ability to launch and market our products, our ability to achieve or sustain profitability, our ability to launch and gain market acceptance for our products and to accurately forecast and meet customer demand, our ability to compete successfully, our ability to enhance our product offerings, development and manufacturing, capacity constraints or delays in production of our products, product defects or failures. These and other risks and uncertainties are described more fully in the "Risk Factors" section and elsewhere in our filings with the Securities and Exchange Commission and available at www.sec.gov, including in our Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. Any forward-looking statements that we make in this announcement speak only as of the date of this press release, and Talis assumes no obligation to updates forward-looking statements whether as a result of new information, future events or otherwise after the date of this press release, except as required under applicable law.

Contact

Media & Investors

Emily Faucette

efaucette@talisbio.com

415-595-9407

Talis Biomedical Corporation

Condensed balance sheets

(in thousands)

                                                March 31,         December 31,
                                                    2022               2021
                                                (unaudited)
Assets
Current assets:
Cash and cash equivalents                       $   187,586       $    232,545
Accounts receivable, net                            2,599              183
Inventory                                           3,499              --
Prepaid expenses and other current assets           7,138              3,387
Total current assets                                200,822            236,115
Property and equipment, net                         10,765             10,528
Operating lease right-of-use-assets                 12,693             12,907
Other long-term assets                              6,307              6,278
Total assets                                    $   230,587       $    265,828
Liabilities and Stockholders' Equity
Current liabilities:
Accounts payable                                $   5,263         $    5,122
Accrued compensation                                4,889              6,369
Accrued liabilities                                 3,496              6,383
Operating lease liabilities, current portion        1,628              1,232
Total current liabilities                           15,276             19,106
Operating lease liabilities, long-term portion      12,526             12,745
Total liabilities                               $   27,802        $    31,851
Stockholders' equity:
Series 1 convertible preferred stock                3                  3
Common stock                                        3                  3
Additional paid-in capital                          600,772            598,913
Accumulated deficit                                 (397,993 )         (364,942 )
Total stockholders' equity                          202,785            233,977
Total liabilities and stockholders' equity      $   230,587       $    265,828

Talis Biomedical Corporation

Condensed Statements of Operations and Comprehensive Loss (Unaudited)

(in thousands)

                                     Three Months Ended March 31,
                                          2022               2021
Revenue
Grant revenue                        $    874           $    7,000
Product revenue, net                      2,313              --
Total revenue, net                        3,187              7,000
Cost of product sold                      3,521              --
Gross profit (loss)                       (334    )          7,000
Operating expenses:
Research and development                  20,703             60,193
Selling, general and administrative       11,930             7,327
Total operating expenses                  32,633             67,520
Loss from operations                      (32,967 )          (60,520 )
Other income (expense), net               (84     )          28
Net loss and comprehensive loss      $    (33,051 )     $    (60,492 )

https://ml.globenewswire.com/media/333984f8-7701-4b9c-a5ce-a836bf670fa1/small/talis-vertical-logo-jpg.jpg

https://ml.globenewswire.com/media/333984f8-7701-4b9c-a5ce-a836bf670fa1/small/talis-vertical-logo-jpg.jpg

comtex tracking

COMTEX_406989775/2010/2022-05-10T16:05:08

Earnings Calendar and Events Data provided by |Terms of Use| © 2022 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., ,, and

Copyright © 2022. All rights reserved.